METHOD FOR DETERMINING HIGH RESIDUAL REACTIVITY OF THROMBOCYTES IN PATIENTS WITH ISCHEMIC HEART DISEASE, WHICH ARE ON ANTIAGGREGANT THERAPY Russian patent published in 2021 - IPC G01N33/49 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cardiology, clinical laboratory diagnostics and hematology. Method for determining high residual reactivity of thrombocytes in patients with ischemic heart disease, receiving Kardiomagnil (75 mg) for 6 months, consists in determining individually to patient dimensions values of aggregates by curve of aggregate size with graphic recording for 5 minutes with constant mixing and temperature of 37°C, adding to thrombocyte-rich inductor plasma aggregation of collagen thrombocytes at ratio of 10:1 in concentration of 2 mcmole/l at 10 second platelet aggregation registration on a laser agglutometer, then in addition to the thrombocyte-rich plasma, an inductor is introduced at ratio of 2:1 2 mcmole/l for 1, 2, 3 and 4 minutes of the study, wherein analysis of results is carried out by curve of sizes of aggregates and when obtaining values of sizes of aggregates of thrombocytes in range from 4.8 to 25 rel. units high residual thrombocyte reactivity is determined.

EFFECT: invention enables high-accuracy detection of high residual reactivity of thrombocytes in patients with ischemic heart disease on antiplatelet therapy.

1 cl, 3 ex